Drug shown to slow Alzheimer’s deemed too costly for NHS
THE Health Secretary was urged today to help the NHS get “fit for the future of dementia” after it emerged that a drug shown to slow Alzheimer’s may not be available on the NHS because of its cost.
Trials found that the drug Lecanemab could slow cognitive decline in early-stage Alzheimer’s patients by 27 per cent over 18 months.
Though approved by the Medicines and Healthcare products Regulatory Agency, the healthcare spending watchdog gave a provisional decision denying access to the treatment on the NHS.
More from this author
Similar stories
Labour’s controversial plan to put the overweight and unemployed on the ‘skinny jab’ Mounjaro should set alarm bells ringing once we look into some of the research into the drug and the company set to supply it, warns CLAUDIA WEBBE
Campaigners slam pledge as a ‘scam’ while Trust leaders say costs have spiralled by 25 per cent